Bcl-2 pathway inhibition in solid tumors: a review of clinical trials.
Ontology highlight
ABSTRACT: Due to their key role in the pathogenesis of cancer through the regulation of apoptosis, the B-cell leukemia/lymphoma-2 (BCL-2) family proteins have been an attractive target for cancer therapy for the past decades. Throughout the years, many Bcl-2 family inhibitors have been developed, with Venetoclax being now successfully used in treating hematological malignancies. Although their effectiveness in the treatment of solid tumors is yet to be established, some preclinical evidence indicates their possible clinical application. This review aims to summarize current data from completed clinical trials that used Bcl-2 protein family inhibitors as monotherapy or in combination with other agents for the treatment of solid malignancies. We managed to include clinical trials of various phases whi
SUBMITTER: Ploumaki I
PROVIDER: S-EPMC10203027 | biostudies-literature | 2023 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA